Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Patterson

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2008
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerRafael G Amado, Michael Wolf, Marc Peeters, et al.
The Journal of Clinical Endocrinology and Metabolism|August 27, 2010
Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancerMichael B Bass, Steven I Sherman, Martin J Schlumberger, et al.
Pharmacogenomics|December 15, 2010
Learning from product labels and label changes: how to build pharmacogenomics into drug-development programsLinda C Surh, Michael A Pacanowski, Susanne B Haga, et al.
Journal for Immunotherapy of Cancer|December 11, 2021
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survivalManish A Shah, David Cunningham, Jean-Philippe Metges, et al.
Proteomics|January 10, 2006
Guidelines for the next 10 years of proteomicsMarc R Wilkins, Ron D Appel, Jennifer E Van Eyk, et al.
Journal of Hepatology|December 16, 2022
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learnedDaniel Guldager Kring Rasmussen, Quentin M Anstee, Richard Torstenson, et al.
The AAPS Journal|March 31, 2011
Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker WorkshopJane P F Bai, Robert Bell, ShaAvhree Buckman, et al.
Pharmacogenomics|July 27, 2011
Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working groupScott D Patterson, Nadine Cohen, Maha Karnoub, et al.
The New England Journal of Medicine|September 13, 2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerJean-Yves Douillard, Kelly S Oliner, Salvatore Siena, et al.
Nature Biotechnology|August 9, 2008
Guidelines for reporting the use of mass spectrometry in proteomicsChris F Taylor, Pierre-Alain Binz, Ruedi Aebersold, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2008
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerRafael G Amado, Michael Wolf, Marc Peeters, et al.
The Journal of Clinical Endocrinology and Metabolism|August 27, 2010
Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancerMichael B Bass, Steven I Sherman, Martin J Schlumberger, et al.
Pharmacogenomics|December 15, 2010
Learning from product labels and label changes: how to build pharmacogenomics into drug-development programsLinda C Surh, Michael A Pacanowski, Susanne B Haga, et al.
Journal for Immunotherapy of Cancer|December 11, 2021
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survivalManish A Shah, David Cunningham, Jean-Philippe Metges, et al.
Proteomics|January 10, 2006
Guidelines for the next 10 years of proteomicsMarc R Wilkins, Ron D Appel, Jennifer E Van Eyk, et al.
Journal of Hepatology|December 16, 2022
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learnedDaniel Guldager Kring Rasmussen, Quentin M Anstee, Richard Torstenson, et al.
The AAPS Journal|March 31, 2011
Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker WorkshopJane P F Bai, Robert Bell, ShaAvhree Buckman, et al.
Pharmacogenomics|July 27, 2011
Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working groupScott D Patterson, Nadine Cohen, Maha Karnoub, et al.
The New England Journal of Medicine|September 13, 2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerJean-Yves Douillard, Kelly S Oliner, Salvatore Siena, et al.
Nature Biotechnology|August 9, 2008
Guidelines for reporting the use of mass spectrometry in proteomicsChris F Taylor, Pierre-Alain Binz, Ruedi Aebersold, et al.
Pageof 6